A 20-year-old cancer vaccine may hold the key to long-term survival

-

 


Two decades after a breast cancer vaccine trial, every participant is still alive—an astonishing result for metastatic disease. Scientists found their immune systems retained long-lasting memory cells primed to recognize cancer. By enhancing a key immune signal called CD27, researchers dramatically improved tumor elimination in lab studies. The findings suggest cancer vaccines may have been missing a crucial ingredient all along.

More than two decades ago, a small group of women with advanced breast cancer took part in a clinical trial that tested an experimental vaccine. All these years later, every one of them is still alive. Researchers say survival over such a long period is extremely uncommon for people with metastatic breast cancer, which is why the case drew renewed scientific attention.

Researchers at Duke Health took a closer look at the immune systems of the women who participated in the trial, which was led by Herbert Kim Lyerly, M.D., George Barth Geller Distinguished Professor of Immunology at Duke University School of Medicine. What they discovered surprised them. Even after many years, the women still had powerful immune cells that could recognize their cancer.

Visit Our Website : toppharmaceutical.org 

Nomination link : https://toppharmaceutical.org/award-nomination/?ecategory=Awards&rcategory=Awardee                                                                                    Contact us : contact@toppharmaceutical.org


#cancervaccine #cancerimmunotherapy #longtermsurvival #oncologyresearch #cancerresearch #therapeuticcancer #immunology #vaccinedevelopment #precisionmedicine #tumorimmunity #clinicaloncology #medicalinnovation #translationalresearch #immuneactivation #cancerbreakthrough #biotechinnovation #personalizedmedicine #futureofoncology #lifesciences #healthcareinnovati


Comments

Post a Comment

Popular posts from this blog

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 November 2024

-
Image
New safety information for healthcare professionals Veoza (fezolinetant): new recommendations to minimise risk of liver injury The PRAC has agreed to a direct healthcare professional communication (DHPC) informing of the risk of drug-induced liver injury (DILI) with Veoza (fezolinetant) and has recommended monitoring of liver function before and during treatment. Veoza is a medicine used to treat moderate-to-severe vasomotor symptoms (also referred to as hot flushes or night sweats) associated with menopause. The committee considered a review of the potential risk of fezolinetant to cause drug-induced liver injury based on information from all available sources, including reports of suspected side effectsand studies published in the scientific literature. Severe elevations of the liver enzymes alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (>10x upper limit of normal) with concurrent elevations in bilirubin and/or alkaline phosphatase (ALP) have been reporte...
Read more

Cell therapy weekly: partnerships for advancing cell and gene therapies

-
Image
This week: Partnerships to advance cell and gene therapies have been announced, focusing on three key areas: developing gene therapies, enhancing cell and gene therapy manufacturing and developing treatments for difficult-to-treat conditions. The news highlights:Centers of excellence for gene therapy research Advancing cell and gene therapy manufacturing Developing therapies for difficult-to-treat conditions Centers of excellence for gene therapy research The Medical Research Centre (MRC), part of UK Research and Innovation (UKRI; both Swindon, UK) is establishing two Centers of Research Excellence (CoRE) to advance therapies for untreatable diseases, each receiving up to roughly US$64 million over 14 years aiming to transform treatments for diseases such as heart disease, immune disorders and neurodegenerative diseases like Huntington’s disease. Oxford University (UK) will lead the MRC/BHF CoRE in Advanced Cardiac Therapies, which will be co-funded with the British Heart Foundati...
Read more